BioLight Life Sciences Azioni (OTC: BLLSF)

Ultime notizie per BioLight Life Sciences (OTC:BLLSF) Azioni

BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.

BIOLIGHT LIFE SCIENCE LTD by BioLight Life Sciences Ltd.

BioLight Life Sciences Ltd

The U.S. Department of the Interior (DOI) will fast-track the environmental review of Anfield Energy's (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ANLDF#OTCQB">ANLDF</a>) Velvet-Wood <a target="_blank" href="https://www.benzinga.com/topic/uranium" rel="noreferrer noopener">uranium</a> and vanadium mine in Utah, completing the process in only 14 days under newly activated emergency authority.
This review is significantly faster than the typical year-long process and is part of President Donald Trump's effort to <a target="_blank" href="https://www.benzinga.com/25/03/44433704/trump-invokes-an-act-from-the-1950s-to-boost-domestic-mineral-industry" rel="noreferrer noopener">boost the domestic mineral industry</a> and <a target="_blank" href="https://www.benzinga.com/news/25/03/44423494/trump-turns-to-beautiful-clean-coal-to-address-domestic-energy-demand" rel="noreferrer noopener">energy production</a>. It is the first project to go through DOI's new emergency permitting process, which is now available to other companies.
The Bureau of Land Management, the agency overseeing the review, follows Trump's executive order from January, when he declared a <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43084601/trump-day-1-executive-order-tsunami-incoming-energy-inflation-immigration-in-focus-but-what-about-tariffs" rel="noreferrer noopener">national energy emergency</a>—an order aimed at scaling up oil, gas, and mineral production.
Interior Secretary Doug Burgum noted that the rapid review demonstrates the administration's urgency to restore American energy dominance.
"America is facing an alarming energy emergency because of the prior administration's climate extremist policies," he <a target="_blank" href="https://www.doi.gov/pressreleases/interior-expedites-permitting-critical-energy-project-address-national-energy" rel="noreferrer noopener">said</a> in a statement. "The expedited mining project review represents exactly the kind of decisive action we need to secure our energy future."
DOI pointed out that uranium and vanadium are critical to national energy and defense needs. Nearly all uranium consumed by U.S. nuclear reactors in 2023 was imported, primarily from Russia and Central Asia, while vanadium demand continues to be met predominantly by overseas producers.
While the government says the fast-track approach removes red tape without compromising oversight, environmental advocates are pushing back. Critics argue that compressing the review timeline eliminates meaningful public input and risks long-term environmental harm.
The founder of Uranium Watch, Sarah Fields, <a target="_blank" href="https://www.nytimes.com/2025/05/12/climate/trump-velvet-wood-uranium-utah.html" rel="noreferrer noopener">told</a> The New York Times that the process "means there's no opportunity for public comment, and the public often brings up issues to the agency that they're not aware of."
Located in San Juan County, Utah, the Velvet-Wood project sits on the historic Velvet mine site, previously active between 1979 and 1984. The site is estimated to hold 4.6 million pounds of uranium and 7.3 million pounds of vanadium in measured, indicated, and inferred resource categories.
The project proposes only three acres of new surface disturbance, using existing underground infrastructure and processing at Anfield's nearby Shootaring Canyon Mill to minimize the environmental impact.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45343504/judge-halts-arizona-land-transfer-to-rio-tinto-citing-native-appeal" target="_blank" rel="noreferrer noopener">Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal</a></li>
</ul>
Photo via Shutterstock

Government

News

Regulations

Commodities

Politics

Small Cap

Legal

Markets

Media

ANLDF

Velvet-Wood Mine First To Use DOI's Fast-Track Permit Process

<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">Robinhood Markets, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has signed an agreement to acquire WonderFi Technologies Inc., a Canadian cryptocurrency platform, in an all-cash transaction valued at approximately $178 million.
What Happened: The purchase price of $0.26 per share represents a 41 percent premium over WonderFi's closing price on May 12 and a 71 percent premium over its 30-day volume-weighted average price, according to a company <a href="https://newsroom.aboutrobinhood.com/robinhood-to-acquire-wonderfi/">statement</a>.
WonderFi operates Bitbuy and Coinsquare, two regulated cryptocurrency exchanges in Canada, with a reported $1.49 billion in assets under custody. 
The company will continue operating its platforms after the transaction closes. 
The deal is expected to be completed in the second half of 2025, subject to shareholder approval, regulatory review and court authorization.
Robinhood, which opened a Canadian headquarters in Toronto in 2024, will incorporate WonderFi's operations into its existing crypto business. 
According to the agreement, WonderFi's leadership team is expected to remain with the company following the acquisition. 
Employees will be added to Robinhood's Canadian workforce, which currently includes over 140 people.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45371362/coinbase-could-see-up-to-16b-net-inflows-after-sp-500-entry-bernstein">Coinbase Could See Up To $16B Net Inflows After S&amp;P 500 Entry: Bernstein</a>
The acquisition will be carried out under a statutory plan of arrangement governed by British Columbia corporate law. 
Robinhood plans to fund the purchase using existing cash reserves. No stock issuance or debt financing will be used to support the transaction.
WonderFi shareholders will receive the full purchase amount in cash. 
The company's common shares are currently listed on the Toronto Stock Exchange. The combined equity value of the transaction, on a fully diluted basis, stands at approximately $178 million.
Advisors on the deal include J.P. Morgan Securities for Robinhood and Financial Technology Partners for WonderFi. 
Legal counsel was provided by Canadian firms on both sides, including Goodmans LLP, Cassels Brock &amp; Blackwell LLP, and Mintz LLP.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45356864/cardano-up-23-in-7-days-as-co-founder-charles-hoskinson-explores-privacy-focused-stablecoin">Cardano Up 23% In 7 Days As Co-Founder Charles Hoskinson Explores Privacy-Focused Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

HOOD

Robinhood To Acquire Canada's WonderFi For $178M All-Cash Deal

SRPT

Japanese Ministry Of Health, Labour, And Welfare Approved Sarepta Theraperutics' ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy Under Conditional And Time-Limited Approval Pathway In Japan

Morgan Stanley analyst Thomas Yeh maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Equal-Weight and raises the price target from $50 to $52.

Price Target

Analyst Ratings

PRKS

Morgan Stanley Maintains Equal-Weight on United Parks & Resorts, Raises Price Target to $52

Barrington Research analyst Kevin Steinke maintains Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) with a Outperform and lowers the price target from $18 to $15.

Barrington Research Maintains Outperform on Superior Gr of Cos, Lowers Price Target to $15

Follow-on expansion phase expected to begin in Q2 2025
THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- –&nbsp;<a href="https://www.globenewswire.com/Tracker?data=hpUlN_MUT2a1PhddJN63J7B98UQYHEUSvTHHFHlsBDbxae2Qs4h1th0tHDKIW5PKfIg7X58qY1k1tek1L--JSpj9uPw9_6iYTYX_4duu5vs=">Autonomix Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial ("PoC 2") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. Additionally, the Company announced the release of a <a href="https://www.globenewswire.com/Tracker?data=XHw77uw22Lrto0jjfo0moarOZ_cF-BMG-V9GE0hm3JL-MO3_CxxtQzETA5IaPGZNm6PTzz4yoENkFlZrdYktFEoRhABUTKnr0m_ubPZGxYeNJkNjHmgXQ897aOZ0_rIdWDvzg5WxwnhS5lUik4LhiQ==">Virtual Investor CEO Connect segment</a> discussing the PoC 2 phase. Access the segment <a href="https://www.globenewswire.com/Tracker?data=MkAQQbXGkp5Dy0Q8lsJPq075xTHjHHXGsm6ZhefGLB80h6vaobiXijiTIIU0wkpIq0GSV0nxpIQflcn064QnjcceqVi7rI7utS4cstk0AHc=">here</a>.
As previously announced, based on the positive results demonstrated in the initial phase of the Company's first-in-human proof-of-concept trial ("PoC 1") in patients with severe pancreatic cancer pain, Autonomix will initiate the follow-on PoC 2 phase in a market expansion opportunity which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain. The Company's PoC 2 phase is on track to commence in the second quarter of 2025.

AMIX

Autonomix Medical Reiterates Plans For Follow-on Phase To PoC 2 Evaluating Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Problematic Nerves And Mitigate Cancer Pain

<ul>
<li>UNH</li>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>BULL</li>
<li>AAPL</li>
<li>AMZN</li>
<li>GOOGL</li>
<li>MSTR</li>
<li>AMD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

AMZN

BULL

GOOGL

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 13, 2025 (Via Swaggy Stocks)

Morgan Stanley analyst Michael Cyprys maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and raises the price target from $76 to $83.

SCHW

Morgan Stanley Maintains Overweight on Charles Schwab, Raises Price Target to $83

Disagrees with ISS' and Glass Lewis' Recommendations which Failed to Address Critical Issues Reiterates The Strength Of Phillips 66's Highly Qualified Board And Nominees
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) today announced that it strongly disagrees with the recommendations issued by Institutional Shareholder Services ("ISS") and Glass Lewis &amp; Co. ("Glass Lewis").
"We disagree with the recommendations issued by ISS and Glass Lewis," said the Phillips 66 Independent Directors. "We remain committed to engaging with and listening to our shareholders on the issues in this campaign."
The Company notes the following issues and omissions in the reports' analyses that remain critical factors for shareholders to consider:
<ul>
<li>Elliott's break-up thesis not examined: The reports did not opine on the merits of Elliott's thesis to break up Phillips 66, which is the primary objective of Elliott's campaign. In fact, ISS stated clearly that its report "is not an endorsement of a Midstream and/or Chemicals separation." Supporting Elliott's directors implicitly supports this risky path and overrides the judgment of Phillips 66's highly qualified Board. Our Board continually evaluates the portfolio to maximize shareholder value and currently believes that the integrated model is the best path to shareholder value creation. As we always have, we remain committed to regularly and aggressively assessing these options going forward. &nbsp;</li>
<li>Concerning assessment of director independence: By recommending against Robert Pease, the reports establish a concerning precedent on evaluating director independence.
<ul>
<li>The reports suggest a director selected and vetted by a shareholder can be determined to lack independence after one month on the board and one vote. The single vote was for a combined CEO and Chair, a policy that is in place at 44% of S&amp;P 500 companies.1</li>
<li>This analysis disregards the fact that Mr. Pease's vote represented his professional judgment as a 30-year corporate leader and ignores the fact that Mr. Pease was carefully evaluated for his qualifications and independence by Elliott. It also fails to apply any scrutiny to Elliott's self-interested lack of support for its recently supported director.</li>
</ul>
</li>
<li>Reliance on board analysis from five years ago: ISS acknowledged that Phillips 66 has refreshed its Board substantially since July 2020. Yet, it still claimed that a lack of Board refreshment prior to the COVID-19 pandemic reflects a need for change now.</li>
<li>Concerning governance overlooked: ISS and Glass Lewis disregarded Elliott's ongoing efforts to acquire CITGO. The reports also overlook the fact that this pursuit took place concurrently with discussions of a second director appointment. Notably, neither report mentions anything about Elliott's misleading disclosures and the overlapping relationships of its director nominees. These are unresolved issues that are highly relevant to shareholder considerations.</li>
</ul>
Phillips 66 reiterates its commitment to ongoing transformation and governance refreshment. The Company reminds shareholders of key facts including:
<ul>
<li>Consistent refreshment: Phillips 66 has added five new independent directors in the past four years to equip the Board with fresh perspectives and independent viewpoints. In its report, ISS acknowledged the Company's board refreshment efforts, noting "Beginning in July 2020, the pace of board refreshment accelerated rapidly. The board appointed Julie Bushman early that month, Lisa Davis in October 2020, Denise Singleton and Doug Terreson in July 2021, and Greg Hayes in July 2022. Mark Lashier also joined in July 2022 in connection with his succession as CEO. Accompanying these appointments, Ferguson departed in August 2020, and McGraw and Tschinkel departed in March 2021."</li>
<li>Strong governance practices: The Board is firmly committed to declassification that would require all directors to stand election each year. The last attempt to do so received approval from 73% of outstanding shares.
<ul>
<li>In its report, ISS supported Phillips 66's declassification proposal, arguing, "The proposed declassification, assuming it can clear the supermajority hurdle, would enhance board accountability to shareholders, and the resubmission of this proposal to a vote after it failed in prior years demonstrates a commitment to shareholders' interests on the part of management."</li>
</ul>
</li>
<li>Early days in transformation strategy: ISS recognizes that Phillips 66 has improved its operating results since Mark Lashier stepped in as CEO on July 1, 2022 and achieved a total shareholder return above that of key competitors. ISS noted, "Since the appointment of Lashier as CEO through May 8, 2025, PSX has outperformed VLO by 20.9 percentage points." Phillips 66 has made it clear that it is working to improve operations but is not satisfied with its results. In under three years, the Company has made progress on corporate cost takeout, refining performance, asset divestitures and more. These are facts recognized by the reports. These actions reflect a commitment to improvement that is continuing and will lead to further performance improvement and ultimately increased shareholder value.</li>
<li>Relevant director skills: Phillips 66's Board composition is closely aligned with the Company's strategy and the issues raised in this campaign. Of the continuing Directors and nominees, six have refining experience, five have chemicals experience and five have midstream experience. The majority has experience in business transformations, several have expertise in finance and a number are experts in supply chains.2 Notably, the Company's Directors and nominees have overseen more than $300 billion in "breakup or major divestiture transactions.3</li>
</ul>
Phillips 66 encourages shareholders to reach their own informed conclusions.
Elliott is seeking rapid, irreversible change in pursuit of a short-term thesis that would introduce significant risks to Phillips 66 shareholders. Do not let Elliott's short-term and misinformed thesis disrupt your consistent and compelling returns.
Phillips 66 recommends that shareholders use the WHITE proxy card to vote:
<ul>
<li>‘FOR' only its four nominees using the WHITE proxy card;</li>
<li>‘FOR' management's proposal to approve the declassification of the Board of Directors, in line with the recommendations from ISS &amp; Glass Lewis;</li>
<li>‘AGAINST' Elliott's proposal requiring annual director resignations, which implementing would violate Delaware law and put your Board at significant legal and reputational risk.</li>
</ul>
The Board strongly recommends that shareholders safeguard their investment in Phillips 66 by casting their vote as soon as possible, regardless of plans to attend the Annual Meeting virtually on May 21, 2025.
Shareholders may receive materials from Elliott Management that say "Gold proxy card" or "Gold voting instructions" or similar language. Phillips 66 recommends that shareholders DISCARD any Gold voting materials they may receive from Elliott. Shareholders may cancel out any vote made using a Gold proxy card by voting again TODAY using the Company's WHITE proxy card. Only the latest-dated vote will count.

Phillips 66 Disagrees With Recommendations Issued By ISS And Glass Lewis; Reiterates Commitment To Ongoing Transformation And Governance Refreshment

BWS Financial analyst Hamed Khorsand maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and maintains $80 price target.

SDRL

BWS Financial Maintains Buy on Seadrill, Maintains $80 Price Target

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091508/Surfing-Bear-1024x683.jpeg" alt="" class="wp-image-12855" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091508/Surfing-Bear-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091508/Surfing-Bear-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091508/Surfing-Bear-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091508/Surfing-Bear.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Bear Market Rally Breaks out</h2>
In a post here last Thursday (<a href="https://www.zerohedge.com/news/2025-05-08/still-bear-market-rally">Still A Bear‑Market Rally?</a>), I argued the April–May bounce was a policy‑fragile technical rally. On Monday, market technicals looked a lot less fragile:&nbsp;
<ol class="wp-block-list">
<li>Breadth thrust&nbsp;– Over 50% of S&amp;P members closed above their 200‑DMA (first time since February).</li>
<li>Index breakout&nbsp;– S&amp;P finished ~1 % above its own 200‑DMA (~5 750).</li>
</ol>
<h2 class="wp-block-heading">Even Pharma Joined In</h2>
Everyone expected a rally on Monday after the ceasefire in the U.S.-China trade war over the weekend. What I didn&#8217;t expect, though, was pharma stocks to join in that rally, in light of President Trump&#8217;s executive order lowering drug prices. In a post written before the market open (<a href="https://www.benzinga.com/general/biotech/25/05/45353526/profiting-from-a-pharma-panic">Profiting From A Pharma Panic</a>), I mentioned about a couple of pharma trades I had teed up if the sector opened in the red:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h3 class="wp-block-heading">Company&nbsp;A – Platform Cash&nbsp;Machine With Royalty Armor</h3>
<ul class="wp-block-list">
<li>Fundamentals 
<ul class="wp-block-list">
<li>Piotroski  F‑Score&nbsp;9 / 9&nbsp;– pristine balance sheet, rising margins, no accounting red flags.</li>
<li>FY‑24 royalty revenue&nbsp;+27 %&nbsp;y/y; operating cash‑flow margin&nbsp;45 %.</li>
<li>Net debt:&nbsp;$‑170 M&nbsp;(yes, net cash) after another quarter of buybacks.</li>
</ul>
</li>
<li>Technicals 
<ul class="wp-block-list">
<li>Price has stair‑stepped higher since October.&nbsp;</li>
<li>Price is above both 50 and 200 day moving averages&nbsp;– a textbook rising channel.</li>
</ul>
</li>
<li>Why MFN risk is minimal 
<ul class="wp-block-list">
<li>Company&nbsp;A doesn't set list prices; its drug‑delivery platform earns a&nbsp;mid‑single‑digit royalty on&nbsp;net&nbsp;sales&nbsp;paid by its partners.</li>
<li>Those partners are market behemoths—Johnson&nbsp;&amp;&nbsp;Johnson&nbsp;(JNJ),&nbsp;Bristol&nbsp;Myers&nbsp;Squibb&nbsp;(BMY),&nbsp;Pfizer&nbsp;(PFE)—that can afford to yank products from low‑margin jurisdictions until pricing equilibrates.</li>
</ul>
</li>
<li>How I'm playing it 
<ul class="wp-block-list">
<li>Bull‑put credit spread: Taking advantage of expensive puts to collect a net credit which we&#8217;ll get to keep if the stock doesn&#8217;t fall further over the next few months.</li>
<li>Equity kicker: Allocate part of that credit to Jan&nbsp;2026&nbsp;OTM calls. Theta from the spread finances the lottery ticket.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;B – The Diabetes Moon‑Shot</h3>
This one is a pure speculative bet—but with asymmetric payoff.
<ul class="wp-block-list">
<li>Catalyst 
<ul class="wp-block-list">
<li>First‑in‑human trial just made its debut participant&nbsp;insulin‑independent after 30&nbsp;years of Type‑1 Diabetes. Not only doesn&#8217;t he need to take insulin, but he doesn&#8217;t need to take any immunosuppressant drugs either. No safety issues so far.&nbsp;</li>
</ul>
</li>
<li>Balance sheet 
<ul class="wp-block-list">
<li>~$800 M cash against a ~$400 M annual burn → roughly&nbsp;24&nbsp;months of runway&nbsp;with zero debt.</li>
</ul>
</li>
<li>Risk 
<ul class="wp-block-list">
<li>Biology can always surprise.</li>
<li>FDA hurdles, capital raises if share price pops.</li>
</ul>
</li>
<li>Position sizing 
<ul class="wp-block-list">
<li>Treat as a&nbsp;lotto ticket: less than 1% of portfolio in common shares—small enough to torch without blinking, big enough to matter if the therapy works.</li>
</ul>
</li>
</ul>
</blockquote>
As it happened,&nbsp;pharma joined in the tariff‑pause relief rally.&nbsp;The&nbsp;Health Care Select Sector SPDR&#xAE; Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) ripped +2.47 %, and my two pharma names both closed in the green. Not the sector you would have expected to join Monday&#8217;s rally, but the move priced me out of clean entries intraday.&nbsp;
<h3 class="wp-block-heading">Maybe We&#8217;ll Get Better Entries Today</h3>
With futures red in the pre-market, that seems possible. If you&#8217;d like a heads up when I place those pharma trades, feel free to subscribe to the Portfolio Armor trading Substack below.&nbsp;
And if you&#8217;d rather limit your risk here, you can download the Portfolio Armor app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image aligncenter size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091554/PA-JPEG-3-1024x683.jpeg" alt="" class="wp-image-12856" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091554/PA-JPEG-3-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091554/PA-JPEG-3-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091554/PA-JPEG-3-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091554/PA-JPEG-3.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091706/Widget-3.jpg" alt="" class="wp-image-12857" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091706/Widget-3.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13091706/Widget-3-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Equities

Options

Opinion

Even Pharma Rallied On Monday

Morgan Stanley analyst Meta Marshall maintains Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) with a Overweight and raises the price target from $156 to $180.

KEYS

Morgan Stanley Maintains Overweight on Keysight Techs, Raises Price Target to $180

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) reported quarterly earnings of $0.10 per share. The company reported $6.09 billion in sales this quarter. This is a 18.83 percent decrease over sales of $7.50 billion the same period last year.

Earnings

FJTSY

Fujitsu Q4 EPS $0.10, Sales $6.09B Down From $7.50B YoY

<a href="https://www.youtube.com/watch?v=KCnhMTA5-qI" title="https://www.youtube.com/watch?v=KCnhMTA5-qI">https://www.youtube.com/watch?v=KCnhMTA5-qI</a>

Macro Economic Events

Economics

General

President Trump And Saudi Crown Prince Sign Mineral And Chip Deals.

NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year.

Earnings Misses

Nuveen Arizona Dividend Advantage Municipal Funds 3

NexGen Energy Q1 EPS $(0.06) Misses $(0.04) Estimate

Needham analyst Chris Pierce reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from Hold to Hold.

Reiteration

BLNK

Needham Reiterates Hold on Blink Chargingto Hold

Morgan Stanley analyst Benjamin Swinburne maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Equal-Weight and raises the price target from $57 to $60.

FOXA

Morgan Stanley Maintains Equal-Weight on Fox, Raises Price Target to $60

Renovaro Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center ("Amsterdam UMC") to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring.
The collaboration will focus on assessing the clinical utility of blood platelet RNA signatures as a powerful biomarker source. This effort will leverage the unique Artificial Intelligence ("AI")/Machine Learning ("ML") capabilities of Renovaro as well as the newly announced compute resources provided through their agreement with Nebul, to uncover subtle disease-specific signals from blood samples and is aimed at transforming diagnostic and prognostic approaches across multiple cancer types.
Under the terms of the agreement, Renovaro and Amsterdam UMC will work together to refine and improve predictive performance, aiming for a high degree of clinical accuracy. The project will involve collection and analysis of blood samples, data integration from multiple modalities, and the development of sophisticated deep learning models.

RENB

Renovaro Agrees On Terms For Exclusive Collaboration Agreement With Amsterdam UMC To Jointly Evaluate And Develop Blood Platelet RNA Diagnostics

Horace Mann Educators Board Authorizes New Share Repurchase Program Of Up To $50M

Morgan Stanley analyst James Faucette maintains i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) with a Equal-Weight and lowers the price target from $27 to $25.

Comments

BioLight Life Sciences

Notizie

Ultime notizie per BioLight Life Sciences (OTC:BLLSF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO